Enteric Muco-Adhesive Levodopa Formulation for Stable Plasma Levels
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing oral levodopa formulations for Parkinson's disease fail to provide steady plasma concentrations, leading to 'peak-to-trough' fluctuations and short duration-of-effect, necessitating improved oral delivery systems that offer rapid 'on' response and prolonged therapeutic levels.
Innovation Solution
A controlled release oral dosage form comprising an immediate release component and a controlled release component, utilizing a muco-adhesive and enteric coating to delay drug release until the small intestine, combined with a rate-controlling material for extended absorption, optionally with a decarboxylase inhibitor like carbidopa.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of time
If oral levodopa is administered to provide rapid therapeutic effect, then the onset time is reduced, but plasma concentration fluctuations increase
Solution Approach 1:
The levodopa dosage is divided into multiple particles or granules with different release characteristics. Some particles provide immediate release for rapid onset, while others are coated with enteric and muco-adhesive materials for controlled release, creating a segmented system that addresses both speed and stability requirements
Solution Approach 2:
The formulation employs a multi-phase release mechanism where different portions of levodopa are released at different rates and times. The immediate release component provides initial therapeutic effect, followed by controlled release phases that maintain steady plasma levels, creating a periodic action pattern that balances onset speed with concentration stability
2Duration of action of moving object
If controlled release materials are used to extend duration of effect, then the duration is prolonged, but the onset time increases
Solution Approach 1:
The formulation contains multiple particle populations with different coating characteristics. Uncoated or lightly coated particles provide immediate release for rapid onset, while particles with enteric and muco-adhesive coatings provide extended controlled release, achieving both fast onset and prolonged duration through segmentation
Solution Approach 2:
The immediate release component acts as a preliminary action that establishes therapeutic levels quickly, while the controlled release components subsequently maintain these levels. This preliminary action ensures rapid onset before the slower controlled release mechanisms take over to extend duration
3Stability of the object's composition
If enteric coating is applied to delay release until small intestine, then plasma concentration stability is improved, but the onset time is delayed
Solution Approach 1:
The formulation segments levodopa into different particle types: some with enteric coating for stable controlled release in the intestine, and others without or with minimal coating for immediate release. This segmentation allows the system to achieve both plasma concentration stability and rapid onset simultaneously
Solution Approach 2:
Different portions of the formulation have different release properties tailored to specific needs. The enteric-coated particles are designed for stable controlled release in the intestinal environment, while uncoated particles provide rapid absorption in the stomach, creating local quality variations that resolve the contradiction
4Duration of action of moving object
If muco-adhesive material is used to prolong intestinal retention, then duration of effect is extended, but device complexity increases
Solution Approach 1:
The formulation merges multiple functions into the muco-adhesive coating layer: it provides controlled release of levodopa, adheres to the intestinal mucosa to prolong retention, and protects the drug during gastric transit. This consolidation of multiple functions into a single coating system extends duration without proportionally increasing complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation provides rapid and sustained plasma levels of levodopa, minimizing fluctuations and extending therapeutic coverage for Parkinson's disease patients.
Implementation Method 1
a muco-adhesive and enteric coating to delay drug release until the small intestine
Implementation Method 2
a muco-adhesive and enteric coating to delay drug release until the small intestine
Implementation Method 3
combined with a rate-controlling material for extended absorption
Data Source
AI summary
The invention provides an oral solid formulation comprising (a) a plurality of controlled release components comprising (i) a core comprising a mixture of levodopa and at least one pharmaceutically acceptable excipient, (ii) a controlled release coating surrounding the core, (iii) a muco-adhesive coating surrounding the controlled release coating and (iv) an enteric coating surrounding the muco-adhesive coating; and (b) one or more immediate release components comprising levodopa. The oral solid formulation also contains carbidopa and about 80% to 100% of the carbidopa in the oral solid formulation is present in the one or more immediate release components.